Fig. 3

Spearman correlations between clinical measures and fold change or baseline NSAF values from label-free proteomic analysis of polyarthritis CSF samples at baseline and after 8 weeks of infliximab treatment (n = 5). a Fold change in ESR correlates positively to fold change in FGG and CFB. b Fold change in HAQ score correlates positively with fold change of FGG and CFB. c Fold change in VAS-pain correlates positively to NSAF values of CNTN1 and CADM3 at baseline. Fold change was calculated according to the formula “(samples following 8 weeks of imfliximab treatment − baseline samples)/baseline samples” and p < 0.05 was considered significant